Furocoumarin-Rich Medicinal Plants for Vitiligo: Phytochemistry, Melanogenic Mechanisms, and Nano-Encapsulation Strategies
Pharmaceutics · 15.11.2026 · 18 (11) · 1475
DOI: 10.3390/pharmaceutics18111475 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 15.11.2026. Verfasst von Abhishek Dadhich und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Depigmentation disorders of the skin remain difficult to manage despite decades of pharmacological development, and current first-line options are constrained by relapse, incomplete response, or dependence on ultraviolet exposure. A family of structurally related plant compounds called furocoumarins, independently adopted by Egyptian, Unani, and Ayurvedic medical traditions centuries before any mechanistic understanding existed, offers a coherent but underexamined therapeutic framework built around a single paradox: the same compound class that causes severe light-induced skin injury at uncontrolled doses restores pigment at controlled, light-activated doses. This review compares seven species from this plant family across the pathogenesis, mechanism, formulation, safety, and clinical-trial literature rather than cataloging phytochemistry alone. Direct interrogation of the literature overturns several assumptions carried by prior reviews of this compound class: a widely assumed co-stimulatory compound within the best-studied species is shown instead to suppress pigment production through an unrelated pathway; one traditional lineage long treated as botanically distinct is shown to rely on the same source plant as another; and clinical evidence, assumed distributed across the family, is shown to be concentrated almost entirely in a single species-derived compound, leaving the most phytochemically documented species without any identified controlled human trial. A previously unexamined pharmacokinetic interaction between this compound class and a newly approved systemic treatment is identified through cross-study inference. Controlled-release formulation strategies are evaluated against what has and has not been directly demonstrated for this specific compound family, revealing that most proposed carrier types remain entirely untested. A three-arm clinical trial design is proposed as the field’s most consequential unmet experiment. Together, these findings reframe furocoumarin phototoxicity as a solvable formulation problem rather than an inherent limit of the compound class, and identify a single, well-defined clinical trial as the most direct route to converting a centuries-old traditional therapy into an evidence-based, dose-controlled treatment option for a condition that current pharmacology has yet to fully resolve.
Zitieren
APA
Dadhich, A., Dhar, I., Padalia, D., Sharma, V., Sharma, S., Chandrasekaran, M., & Sivanesan, I. (2026). Furocoumarin-Rich Medicinal Plants for Vitiligo: Phytochemistry, Melanogenic Mechanisms, and Nano-Encapsulation Strategies. Pharmaceutics, 18(11), 1475. https://doi.org/10.3390/pharmaceutics18111475
Vancouver
Dadhich A, Dhar I, Padalia D, Sharma V, Sharma S, Chandrasekaran M, et al. Furocoumarin-Rich Medicinal Plants for Vitiligo: Phytochemistry, Melanogenic Mechanisms, and Nano-Encapsulation Strategies. Pharmaceutics. 2026;18(11):1475. doi:10.3390/pharmaceutics18111475
BibTeX
@article{Dadhich2026,
author = {Dadhich, Abhishek and Dhar, Irra and Padalia, Diwakar and Sharma, Vikas and Sharma, Shivika and Chandrasekaran, Murugesan and Sivanesan, Iyyakannu},
title = {Furocoumarin-Rich Medicinal Plants for Vitiligo: Phytochemistry, Melanogenic Mechanisms, and Nano-Encapsulation Strategies},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {11},
pages = {1475},
doi = {10.3390/pharmaceutics18111475}
}
EUVIMED